High-dose targeted therapy for advanced stages of Ph+ Chronic Myeloid Leukemia (CML), malignant Gastrointestinal Stromal Tumors (GIST), and aggressive systemic mastocytosis.
High-dose targeted therapy for advanced stages of Ph+ Chronic Myeloid Leukemia (CML), malignant Gastrointestinal Stromal Tumors (GIST), and aggressive systemic mastocytosis.
Binds tightly to the inactive conformation of the BCR-ABL tyrosine kinase domain. This prevents autophosphorylation, blocking cellular signals that cause rapid white blood cell cloning and tumor advancement.
Severe peripheral edema, gastrointestinal bleeding, severe bone/muscle pain, skin desquamation, hepatotoxicity, and cytopenias.
The 400mg strength provides the standard full daily therapeutic dose for adult CML in a single, convenient tablet, improving patient adherence.
Yes, Imatinib tablets can be dispersed in a glass of water or apple juice, stirred thoroughly, and consumed immediately.
Rapid, unexplained weight gain, shortness of breath, and swelling of the lower extremities or eyelids.
It can induce neutropenia and leukopenia, leaving the patient more vulnerable to bacterial or viral opportunistic infections.
Yes, rare cases of congestive heart failure and left ventricular dysfunction have been linked to long-term TKI usage.
Higher doses place a greater metabolic load on the liver. Transaminase levels must be checked regularly, and the drug paused if enzymes spike over 5 times the upper limit of normal.
Any brand switch should be explicitly managed by the supervising oncologist to ensure consistent bioavailability and drug absorption levels.
Yes, erythematous or maculopapular skin eruptions occur in roughly one-third of patients and are usually managed with antihistamines or low-dose steroids.
Imatinib has poor central nervous system penetration, making it less effective for active intracranial leukemic disease or brain metastases.
Store in the original moisture-resistant blister pack at room temperature below 30?C, away from direct heat and damp environments.